Info: Zenodo’s user support line is staffed on regular business days between Dec 23 and Jan 5. Response times may be slightly longer than normal.

Published July 11, 2022 | Version V1.0
Project deliverable Open

Plan for dissemination including communication activities

  • 1. accelopment Schweiz AG
  • 2. Johann Wolfgang Goethe Universität Frankfurt am Main
  • 3. F4 Pharma GmbH
  • 4. European Society of Anaesthesiology and Intensive Care

Description

This deliverable D8.3 presents the COVend plan for dissemination, including communication activities and describes the main strategy of the COVend consortium to maximise its project impact. In sections 2 and 3, we outline our communication strategy by defining in detail the six target groups established for the project and our key messages, as well as the tools and channels the COVend consortium will use to reach all target groups. Furthermore, in Section 4 this plan details the specific communication and dissemination activities to be pursued in the duration of the project, as well as the respective partner responsibilities. Evaluation metrics and targets in section 5 are set to guide the impact assessment throughout the project. Exploitation measures for the drug developed by the COVend project are also briefly considered, but will be further developed in the Roadmap for Exploitation (D8.6). Tailored to the COVend stakeholders, this plan is designed to be flexible and easily maintained, with foreseen updates throughout the project’s duration. This will ensure that the communication and dissemination activities are always created and delivered to reach maximum impact among all stakeholder groups.

Files

COVend_D8.3_Plan for dissemination including communication activities.pdf

Additional details

Funding

COVend – Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19 101045956
European Commission